Canada Drugs Direct

Visiting from Canada?

Want to save up to 80% on your medications? Signup below to be notified if we open a Canadian Online Pharmacy.

I agree to receive email updates from Canada Drugs Direct

Looking for Call us toll free 1-800-500-2897

Imfinzi (Durvalumab)

Prescription medicineOnly Available By Prescription

What if I find a lower price with another pharmacy?

We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!

Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.

To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.

Terms & Conditions of Program

  • Guaranteed lowest price is only valid at the time of sale.
  • We will only match the current advertised price.
  • Products must be identical and in stock at the time of placing an order with a licensed mail order pharmacy. The must be a member of CIPA (Canadian International Pharmacy Association).
  • Products must be authentic in brand and size (same manufacturer, same country of manufacture, same pack size, same strength and same quantity).
  • Products must be new. We cannot match the price of any used, short expiry or expired product.
  • Price match can only be issued over the phone with our customer service team
What is a Generic Drug?

A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.

The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.

Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.


Imfinzi (Durvalumab) is a prescription medicine used as an immunotherapy treatment for certain types of cancer. It helps the immune system to fight cancer by blocking a specific protein called programmed death-ligand 1 (PD-L1). By blocking PD-L1, Imfinzi may improve the body's immune response, allowing it to target and attack cancer cells more effectively. The drug's primary use is for the treatment of extensive-stage small cell lung cancer (ES-SCLC) and unresectable Stage III non-small cell lung cancer (NSCLC). Imfinzi is also used in certain cases of bladder, lung, and biliary tract cancer.

Fact Table




US DailyMed



Legal status


Chemical Name


Elimination half-life

18 days

Dosage (Strength)

50mg/mL (2.4-mL, 10-mL single-dose vials)


Consult Doctor



Protein binding


PubChem CID





Not Assigned

ATC code






Routes of administration



The recommended dosage for Imfinzi varies depending on the specific cancer being treated and patient factors, such as weight. It is typically administered as an intravenous (IV) infusion in a healthcare setting. Your healthcare provider will determine the best dosage and schedule for your condition.


The active ingredient in Imfinzi is Durvalumab. In addition to Durvalumab, Imfinzi also contains several inactive ingredients; these substances do not have a direct therapeutic effect but help create a stable, injectable solution. Some of the inactive ingredients include L-histidine, L-histidine hydrochloride monohydrate, a,a-trehalose dihydrate, polysorbate 80, and water for injection.


There are no contraindications labeled on the drug package insert. If you have a history of allergic or severe infusion reactions, Imfinzi use may need to be carefully considered and potentially avoided.


  • Before starting treatment with Imfinzi, it is important to discuss with your healthcare provider:
    • Any medical conditions, including immune system problems, conditions that affect the nervous system.
    • If you’ve received chest radiation therapy or an organ or stem cell transplant.
    • If you’re pregnant or breastfeeding or plan to.
  • Imfinzi can cause serious or even fatal immune-mediated adverse reactions. These can affect any organ system or tissue and may include conditions such as pneumonitis, colitis, hepatitis, endocrinopathies, skin reactions, nephritis and renal dysfunction, solid organ transplant rejection, and pancreatitis.
  • Monitor for signs of adverse reactions early. Liver enzymes, creatinine, and thyroid function should be checked before treatment and periodically thereafter.
  • Depending on the severity and the type of immune-mediated reaction, treatment with Durvalumab may need to be withheld or permanently discontinued.
  • If you experience an infusion-related reaction, the infusion may need to be interrupted, the rate of infusion slowed, or the treatment permanently discontinued, based on the reaction's severity.
  • For patients who have undergone or will undergo allogeneic hematopoietic stem cell transplantation (HSCT), there is a risk of fatal and other serious complications when treated with PD-1/PD-L1 blocking antibodies like Durvalumab.
  • Durvalumab can cause harm to a fetus. Women of reproductive potential should be advised about this risk and counseled on the use of effective contraception.

Side Effects

Imfinzi may cause a range of side effects. The most common side effects of Imfinzi include cough, fatigue, pneumonitis or radiation pneumonitis, infections of the upper respiratory tract, shortness of breath, and skin rash.

Imfinzi can cause serious side effects including lung issues like persistent cough and chest pain, intestinal problems such as severe abdominal pain or bloody stools, liver complications indicated by yellowing of the skin and dark urine, hormone gland changes leading to persistent headaches and unusual mood swings, and kidney problems like reduced urine output or blood in the urine. Seek immediate medical attention if you experience any of these severe symptoms or symptoms of infusion reactions, such as flushing, fever, rash, and muscle or joint pain.


  1. Imfinzi (Durvalumab) Imfinzi Package Insert. Wilmington, DE: AstraZeneca Pharmaceuticals; 2023.
  2. Imfinzi (Durvalumab) Drug Label Information. Wilmington, DE: AstraZeneca Pharmaceuticals; 2023.

IMPORTANT NOTE: The above information is intended to increase awareness of health information and does not suggest treatment or diagnosis. This information is not a substitute for individual medical attention and should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. See your health care professional for medical advice and treatment.

product reviews icon Product Reviews